Review Article
Gene Therapy (2008) 15, 780–786; doi:10.1038/gt.2008.36; published online 27 March 2008
Endothelial progenitor cells for cancer gene therapy
K-M Debatin1, J Wei1 and C Beltinger1
1University Children's Hospital, Ulm, Germany
Correspondence: Professor C Beltinger, University Children's Hospital, Eythstr. 24, Ulm 89075, Germany. E-mail: christian.beltinger@uniklinik-ulm.de
Received 14 February 2008; Accepted 16 February 2008; Published online 27 March 2008.
Abstract
Endothelial progenitor cells (EPCs) are promising for cancer therapy because they specifically target tumors. They have the capacity to home to, invade, migrate within and incorporate into tumor structures. They are easily expanded and can be armed with therapeutic payloads protected within the progenitor cells. Once in the tumor, armed EPCs can be triggered to induce cell death in surrounding tumor cells while being transiently protected from premature demise. In preclinical studies, therapeutic EPCs attenuated tumor growth and increased survival. Enhancing homing, self-protection and collateral tumor cell damage will increase the efficacy of EPCs for cancer gene therapy.
Keywords:
endothelial progenitor cells, cellular vehicle, cancer
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Vascular dysfunction in idiopathic dilated cardiomyopathy
Nature Reviews Cardiology Review (01 Sep 2009)
NEWS AND VIEWS
Nature Medicine News and Views (01 Sep 2002)
Nimble progenitors rescue vascular grafts
Nature Medicine News and Views (01 Sep 2001)
RESEARCH
Kidney International Original Article
Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy
Gene Therapy Original Article
